Key Points
- Rhythm CAO Christopher Paul German sold 5,614 shares on March 4 at an average price of $89.56 for proceeds of $502,789.84, leaving him with 160 shares — a 97.23% reduction in his position.
- In the quarter ended Feb. 26 the company beat estimates with EPS of ($0.73) vs. ($0.79) expected and revenue of $57.25M (up 36.9% YoY), but remains unprofitable with a negative net margin (~103.6%) and negative ROE.
- Wall Street sentiment is broadly positive: the stock carries a consensus rating of Moderate Buy with a consensus target of $132.07 and multiple firms issuing Buy/Overweight ratings (targets ranging roughly $125–$150).
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CAO Christopher Paul German sold 5,614 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total transaction of $502,789.84. Following the completion of the transaction, the chief accounting officer directly owned 160 shares in the company, valued at approximately $14,329.60. This represents a 97.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Rhythm Pharmaceuticals Price Performance
Shares of RYTM opened at $93.52 on Friday. The company has a market capitalization of $6.39 billion, a PE ratio of -30.07 and a beta of 2.06. Rhythm Pharmaceuticals, Inc. has a one year low of $45.90 and a one year high of $122.20. The company's fifty day moving average price is $101.91 and its 200 day moving average price is $103.31.
Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.06. The company had revenue of $57.25 million during the quarter, compared to analysts' expectations of $56.16 million. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The business's quarterly revenue was up 36.9% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.72) earnings per share. Analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on RYTM. Stifel Nicolaus set a $131.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Thursday, February 26th. UBS Group restated a "buy" rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, December 17th. Canaccord Genuity Group reduced their target price on shares of Rhythm Pharmaceuticals from $141.00 to $140.00 and set a "buy" rating for the company in a research note on Monday, March 2nd. Morgan Stanley restated an "overweight" rating and set a $150.00 price target on shares of Rhythm Pharmaceuticals in a research note on Thursday, December 11th. Finally, Jefferies Financial Group reiterated a "buy" rating and issued a $125.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $132.07.
Read Our Latest Report on Rhythm Pharmaceuticals
Institutional Trading of Rhythm Pharmaceuticals
A number of institutional investors and hedge funds have recently added to or reduced their stakes in RYTM. EverSource Wealth Advisors LLC lifted its stake in Rhythm Pharmaceuticals by 303.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company's stock worth $28,000 after purchasing an additional 200 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of Rhythm Pharmaceuticals by 97.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company's stock valued at $29,000 after purchasing an additional 141 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of Rhythm Pharmaceuticals by 1,110.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 351 shares of the company's stock worth $35,000 after buying an additional 322 shares in the last quarter. Optiver Holding B.V. lifted its position in shares of Rhythm Pharmaceuticals by 65.2% during the 3rd quarter. Optiver Holding B.V. now owns 365 shares of the company's stock worth $37,000 after buying an additional 144 shares during the period. Finally, SBI Securities Co. Ltd. lifted its position in shares of Rhythm Pharmaceuticals by 73.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 343 shares of the company's stock worth $37,000 after buying an additional 145 shares during the period.
About Rhythm Pharmaceuticals
(
Get Free Report)
Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company's research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.
The company's lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
